Scheduled Maintenance Notice: ESG NextGen Platform Downtime on May 17, 2025
Author: masuuglobal
The Role of Artificial Intelligence Within the Pharmaceutical Sector
The Role of Artificial Intelligence Within the Pharmaceutical Sector: Businesses in a fast-changing world have always taken advantage of the market’s opportunity to improve their processes, making them smarter, more effective. With the help of Al and machine learning, companies are able to reach their peak efficiency in data analysis that will leave an enormous impact on each other’s… Continue reading The Role of Artificial Intelligence Within the Pharmaceutical Sector
Navigating EMA’s Updated Paediatric Application Procedures: April 2025 Insights
Navigating EMA’s Updated Paediatric Application Procedures: April 2025 Insights On 15 April 2025, the European Medicines Agency (EMA) released an updated version (Rev. 121) of its procedural advice on paediatric applications (EMA/672643/2017). This revision reflects the agency’s commitment to streamlining regulatory processes, enhancing transparency, and supporting innovation in paediatric medicine development across the EU.
Understanding ACA Section 6004: Ensuring Drug Safety and Transparency in Healthcare
Understanding ACA Section 6004: Ensuring Drug Safety and Transparency in Healthcare On March 23, 2010, the Affordable Care Act (ACA) was signed into law. Among other things, the ACA amends the Social Security Act, 42 U.S.C. 1301 et seq., by adding section 6004. This new section requires the submission of certain drug sample information to… Continue reading Understanding ACA Section 6004: Ensuring Drug Safety and Transparency in Healthcare
Risk Evaluation and Mitigation Strategies (REMS) Overview
Risk Evaluation and Mitigation Strategies (REMS) The Food and Drug Administration Amendments Act (FDAAA) of 2007, signed on September 27, 2007, by President George W. Bush, created section 505-1 of the Food, Drug, and Cosmetic Act (FD&C Act) which authorizes FDA to require a Risk Evaluation and Mitigation Strategies (REMS) for certain drugs if FDA… Continue reading Risk Evaluation and Mitigation Strategies (REMS) Overview
MHRA Launches New Monthly Safety Roundup Bulletin and Redesigned Safety Alerts
MHRA Launches New Monthly Safety Roundup Bulletin and Redesigned Safety Alerts The MHRA has introduced a new monthly safety bulletin, the MHRA Safety Roundup, as part of its three-year strategy to enhance safety communications. This initiative aims to make information about medicines and medical devices clearer and more accessible for healthcare professionals.
Guideline for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products
Guideline for the Use of Artificial Intelligence (AI) to Support Regulatory Decision-Making for Drug and Biological Products Artificial Intelligence (AI) is rapidly transforming various industries, including the pharmaceutical sector. Regulatory authorities are increasingly exploring AI-driven tools to enhance decision-making processes related to drug and biological product approvals. However, the integration of AI in regulatory science… Continue reading Guideline for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products
CARES Act Section 505G: Modernizing OTC Drug Monographs
CARES Act Section 505G: Modernizing OTC Drug Monographs The CARES Act, signed into law on March 27, 2020, brought significant changes to the regulatory framework governing Over-the-Counter (OTC) drugs in the U.S. Section 505G, which was added to the Federal Food, Drug, and Cosmetic (FD&C) Act, specifically addresses OTC monograph drugs and aims to modernize… Continue reading CARES Act Section 505G: Modernizing OTC Drug Monographs
Pharmacovigilance System Master File (PSMF): Its Importance and Regulatory Role in Ensuring Drug Safety
Pharmacovigilance System Master File (PSMF): Its Importance and Regulatory Role in Ensuring Drug Safety The Pharmacovigilance System Master File (PSMF) is a key regulatory requirement under the EU pharmacovigilance legislation, ensuring that medicinal products authorized in the European Union (EU) comply with the stringent safety monitoring and reporting standards. Its primary objective is to provide… Continue reading Pharmacovigilance System Master File (PSMF): Its Importance and Regulatory Role in Ensuring Drug Safety
FDA Modernizes the Electronic Submission Gateway (ESG) with ESG NextGen
FDA Modernizes the Electronic Submission Gateway (ESG) with ESG NextGen The FDA is launching ESG NextGen, a modern, cloud-based system designed to improve the submission process. Key features include a unified submission portal, real-time tracking, enhanced cybersecurity, and API integration. This modernization expands bandwidth and storage capacity, allowing for a more seamless and efficient experience.